FDA approves Biogen hemophilia drug

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen's (BIIB) Elocate has been approved for "the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with hemophilia A."

Biogen declares Elocate is "the only treatment for hemophilia A to reduce the frequency of bleeding episodes with prophylactic infusions every three to five days."

The drug is expected to be launch in the U.S. in July.

BIIB +0.5% AH.